Table 2.
Number and frequency of total cholesterol measurements by type of regimen and cohort.
| cART Regimen | AHOD No. of patients* | AHOD median (range) no. of measurements per patient | AHOD no. (%) of measurements | TAHOD no. of patients* | TAHOD median (range) no. of measurements per patient | TAHOD no. (%) of measurements |
|---|---|---|---|---|---|---|
| NRTIs (+TDF) + NVP | 122 | 2 (1–6) | 247 (10.8) | 70 | 1 (1–4) | 108 (1.9) |
| NRTIs (+TDF) + EFV | 131 | 2 (1–4) | 245 (10.7) | 90 | 1 (1–4) | 147 (2.6) |
| NRTIs + NVP | 155 | 2 (1–6) | 342 (14.9) | 696 | 1 (1–8) | 1157 (20.6) |
| NRTIs + EFV | 97 | 2 (1–4) | 211 (9.2) | 684 | 2 (1–10) | 1487 (26.5) |
| NRTIs (+TDF) + PI (+ATV) | 140 | 1 (1–5) | 266 (11.6) | 20 | 1 (1–4) | 28 (0.5) |
| NRTIs (+TDF) + PI | 187 | 2 (1–7) | 410 (17.9) | 137 | 3 (1–6) | 367 (6.5) |
| NRTIs + PI (+ATV) | 78 | 2 (1–5) | 178 (7.7) | 232 | 3 (1–6) | 610 (10.9) |
| NRTIs + PI | 184 | 2 (1–6) | 396 (17.2) | 620 | 3 (1–12) | 1698 (30.3) |
|
| ||||||
| Total | 1094 | 2295 (100) | 2548 | 5602 (100) | ||
*Each patient could contribute to more than one regimen. AHOD: Australian HIV Observational Database; ATV: Atazanavir; EFV: Efavirenz; NNRTI: non- nucleoside reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; NVP: nevirapine; PI: protease inhibitor; TAHOD: TREAT Asia HIV Observational Database; TDF: tenofovir. Key. NRTIs are TDF based (NRTIs + TDF) or not (NRTIs) and PI as ATV based (PI + ATV) or not (PI).